BPC-157 and TB-500 are research peptides promoted for injury recovery, inflammation, and tissue repair. The strongest evidence is not equal: BPC-157 has limited small human studies, while TB-500 claims mostly rely on thymosin beta-4 biology or preclinical research. Benefits are not established, and use should be discussed with a licensed clinician.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What are the quick facts about BPC-157 and TB-500?
BPC-157 and TB-500 are best understood as investigational peptides, not proven recovery treatments. In the published and registered evidence supplied here, BPC-157 has more direct human data than TB-500, but the studies are still small or early.
For BPC-157, human evidence includes a small knee pain study and a pilot interstitial cystitis study, plus registered trials that are still answering open questions about muscle strain and surgical recovery 1 2 3 4. For TB-500, most claims are extrapolated from thymosin beta-4, also written Tβ4, and from animal or cell work rather than direct TB-500 patient outcomes 5.
The bottom line is simple: a promising mechanism does not equal a proven human benefit. If you want a broader primer, our guide to what peptides do explains how peptide signals can look strong in a lab but still fail to become safe, useful treatments for people.
What are BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid peptide based on a body-protection compound first studied in gastric and tissue-repair models. TB-500 is commonly marketed as a thymosin beta-4 fragment, but the research trail for thymosin beta-4 should not be treated as proof that TB-500 injections help patients.
BPC-157
BPC-157, also called Body Protection Compound 157, pentadecapeptide BPC 157, or PL 14736, has been studied for possible roles in blood-vessel signaling, inflammation pathways, collagen biology, and soft-tissue healing models. Reviews describe many animal and cell findings, but those findings do not prove patient outcomes for tendon injury, ligament injury, muscle strain, knee pain, or post-surgical healing 6 7.
TB-500
TB-500 is discussed in wellness circles as a synthetic peptide linked to thymosin beta-4 research. Thymosin beta-4 is involved in actin regulation, cell migration, angiogenesis, and wound-healing biology, but indirect thymosin beta-4 findings are not the same as direct evidence that TB-500 improves recovery in humans 5.
Why the term “Wolverine stack” can be misleading
The “Wolverine stack” is a nickname for using BPC-157 and TB-500 together. It is not an FDA label, a professional guideline, or a standard protocol. We cover the same safety issue in our article on the Wolverine stack: catchy names can make uncertain evidence feel more established than it is.
What benefits do people claim from BPC-157 and TB-500?
BPC-157 and TB-500 benefits are commonly claimed for soft-tissue recovery, tendon injury, ligament injury, muscle strain, inflammation, pain, wound healing, and sometimes hair growth. The problem is that most claims are not backed by strong human outcome trials.
- Soft-tissue recovery: BPC-157 reviews describe animal and laboratory work in musculoskeletal soft-tissue models, but this is not the same as proven faster recovery in people 6.
- Tendon, ligament, and muscle repair: registered BPC-157 trials for acute hamstring strain and rotator cuff repair show that these questions are still being studied, not settled 3 4.
- Inflammation and pain: a completed trial of peptide gummies evaluated markers of inflammation, performance, and recovery, but without published results in the supplied evidence, no efficacy claim should be made 8.
- Hair growth: TB-500 hair-growth claims are usually based on broad thymosin beta-4 or wound-biology ideas, not controlled TB-500 hair-growth trials in humans 5.
Any discussion of possible benefit has to include safety limits. Injection reactions, contamination risk, unknown long-term effects, drug interactions, surgery timing, and sports rules can matter as much as the hoped-for outcome.
What human evidence exists for BPC-157?
BPC-157 has limited human evidence, including small studies in knee pain and interstitial cystitis. These studies are useful signals, but they do not prove broad injury-recovery benefits or define long-term safety.
Small human knee pain study
Lee and Padgett published a human study of intra-articular BPC 157 for multiple types of knee pain in 2021 1. This is direct human evidence, but it should not be stretched into a claim that BPC-157 heals all knee injuries, tendon injuries, or ligament injuries.
Pilot interstitial cystitis study
A 2024 pilot study evaluated BPC-157 for symptoms in patients with interstitial cystitis 2. Pilot studies can help decide what to test next, but they are not definitive proof of benefit, and they do not answer questions about sports recovery or post-surgical healing.
Registered trials
ClinicalTrials.gov lists a recruiting phase 2 study of BPC 157 for acute hamstring muscle strain repair with planned enrollment of 120 participants, and a not-yet-recruiting phase 1 study of BPC-157 after rotator cuff repair with planned enrollment of 30 participants 3 4. These registrations show the field is active, not that the answers are already known.
A phase 1 safety and pharmacokinetics trial for PCO-02 is also registered with planned enrollment of 42 participants, but trial registration alone does not prove clinical benefit 9.
What human evidence exists for TB-500 or thymosin beta-4?
TB-500 has much weaker direct human evidence than BPC-157 in the supplied sources. The key point is that thymosin beta-4 is not the same thing as TB-500, and indirect biology should not be sold as patient benefit.
One randomized study in chronic ischemic heart failure reported that increases in plasma Tβ4 after intracardiac cell therapy were associated with symptomatic improvement 5. That finding is about plasma thymosin beta-4 after a heart cell-therapy procedure; it does not prove that TB-500 helps tendon injury, muscle strain, hair growth, inflammation, or post-surgical recovery.
This matters because many online TB-500 claims move too quickly from “thymosin beta-4 is involved in repair biology” to “TB-500 will repair my injury.” Those are different claims. The second one needs controlled human TB-500 outcome trials.
How do BPC-157 and TB-500 compare?
BPC-157 vs TB-500 is not a close evidence tie. Based on the supplied human evidence, BPC-157 has more direct patient data, while TB-500 claims rely more on mechanism, thymosin beta-4 biology, and preclinical reasoning.
| Question | BPC-157 | TB-500 |
|---|---|---|
| What is it? | Synthetic 15-amino-acid peptide also called Body Protection Compound 157, pentadecapeptide BPC 157, or PL 14736. | Synthetic peptide commonly described as a thymosin beta-4 fragment. |
| Main proposed mechanisms | Studied for tissue-repair signaling, inflammation pathways, blood-vessel effects, and collagen-related processes in models 6 7. | Linked to thymosin beta-4 biology, including actin regulation, cell migration, angiogenesis, and wound-healing pathways 5. |
| Common claims | Knee pain, tendon injury, ligament injury, muscle strain, gut symptoms, inflammation, and recovery. | Soft-tissue recovery, muscle injury, inflammation, flexibility, endurance recovery, and hair growth. |
| Human evidence | Small knee pain study, pilot interstitial cystitis study, and registered trials for hamstring strain and rotator cuff repair 1 2 3 4. | No direct controlled TB-500 outcome trials in the supplied evidence; indirect thymosin beta-4 human findings should not be treated as TB-500 proof 5. |
| Safety unknowns | Long-term safety, best route, dose, duration, interaction risks, and product quality remain uncertain. | Long-term safety, product identity, purity, sterility, dosing, and whether thymosin beta-4 findings apply remain uncertain. |
If you are comparing these peptides because you saw them discussed together online, read our deeper guide on BPC-157 and TB-500 together. The main takeaway is that combination use has even less direct evidence than either peptide alone.
Can you take BPC-157 and TB-500 every day?
BPC-157 and TB-500 do not have an established patient dosing schedule, daily-use plan, cycle length, or evidence-based stack ratio. Online protocols are not the same as clinician-guided, evidence-based dosing.
We will not provide injection instructions or dosing directions for these peptides. The current evidence does not define who should use them, how often, by which route, for how long, or with what monitoring. Registered BPC-157 trials may help answer some of these questions, but a trial listing is not a patient protocol 3 4 9.
If you are thinking about any recovery peptide, a clinician should first ask what diagnosis is being treated. A tendon rupture, ligament tear, stress fracture, infection, nerve injury, or post-surgical complication may need imaging, rehab, medication, or urgent care—not self-experimentation.
What are the possible side effects and safety concerns?
BPC-157 and TB-500 side effects are not fully mapped in long-term human studies. The biggest practical risks are unknown long-term safety, injection-related problems, poor product quality, and using peptides instead of getting the right diagnosis.
- Injection risks: redness, pain, bleeding, infection, sterile abscess, and dosing errors can occur with injected products.
- Product-quality risks: online or research-use-only products may have identity, sterility, purity, labeling, and dosing problems.
- Liver safety: the supplied evidence does not establish that BPC-157 is “hard on the liver,” but it also does not prove long-term liver safety for broad patient use.
- Surgery risks: peptides used around surgery could complicate care if your surgeon and anesthesia team do not know about them.
- Medication risks: people taking blood thinners, immune-active drugs, hormone therapies, diabetes medications, or multiple prescriptions need individualized review.
- Sports risks: athletes should check the rules of their governing body before using any research peptide.
Safety should be judged by the same standard as benefit: human data. For BPC-157, reviews and early human studies leave many open questions 1 2 6 7. For TB-500, direct human safety and outcome evidence is even thinner in the supplied sources 5. Our article on BPC-157 and TB-500 side effects goes deeper on this risk-first view.
How long does it take to see results from BPC-157 or TB-500?
BPC-157 and TB-500 timelines from forums or social media are not reliable medical evidence. Recovery depends on the injury type, baseline health, rehab plan, sleep, nutrition, medications, and whether the diagnosis is correct.
For example, a mild muscle strain and a full-thickness tendon tear can feel similar early on but need very different care. A peptide cannot replace a proper exam, imaging when needed, physical therapy, load management, or surgical follow-up.
Lack of rapid improvement should not be treated as a reason to escalate a peptide dose or add more compounds. Worsening pain, swelling, weakness, fever, numbness, inability to bear weight, or new loss of function should prompt medical evaluation.
Does Chia offer BPC-157 or TB-500?
Chia does not currently list BPC-157 or TB-500 in our live treatment catalog. That means we are not presenting either peptide as something Chia prescribes, sells, compounds, or ships.
At Chia, we write about peptides because patients are already seeing claims online and deserve a clear, evidence-led explanation. Our safety lens is licensed care versus unlicensed self-experimentation: a licensed clinician can help sort out the diagnosis, evidence limits, medication risks, and whether better-studied options should come first.
For patients exploring peptide safety more broadly, we recommend starting with education before access. Useful next reads include what peptides do, BPC-157 and TB-500 together, and the Wolverine stack.
What should you ask a clinician before considering recovery peptides?
Before considering recovery peptides, ask whether the problem has a clear diagnosis and whether standard care has been addressed. A short visit can prevent weeks of guessing.
- 1What diagnosis best explains my pain, weakness, swelling, or limited motion?
- 2Do I need imaging, labs, physical therapy, bracing, medication, or surgical follow-up?
- 3What human evidence applies to my condition, not just to animals, cells, or a different disease?
- 4What side effects or interactions matter with my health history and medications?
- 5Could a research-use-only or online peptide product have purity, sterility, identity, or labeling problems?
- 6If I compete in sports, could this violate anti-doping rules?
- 7What signs mean I should stop self-care and get urgent medical help?
These questions are more useful than asking which peptide is “stronger.” In recovery medicine, the right diagnosis and rehab plan usually matter more than the newest compound.
FAQ: BPC-157 and TB-500 benefits
No. BPC-157 has limited small human studies and ongoing registered trials, but it is not proven to broadly heal injuries faster. TB-500 has even less direct human outcome evidence.
Some people discuss this combination as the “Wolverine stack,” but that name is not a medical protocol. Combination use has less direct evidence than either peptide alone and should not be done without clinician review.
The supplied evidence does not prove that BPC-157 is hard on the liver, but it also does not prove long-term liver safety for broad use. People with liver disease or abnormal labs should speak with a clinician before using any peptide.
There is no reliable, evidence-based timeline for BPC-157 results across injuries. Recovery depends on the diagnosis, injury severity, rehab, sleep, nutrition, medications, and overall health.
TB-500 hair-growth claims are not established by direct controlled human TB-500 trials in the supplied evidence. Many claims come from thymosin beta-4 biology, which should not be treated as proof of TB-500 benefit.
They do not have established FDA-approved uses for injury recovery, inflammation, hair growth, or post-surgical healing in the evidence reviewed here. Chia does not currently offer BPC-157 or TB-500.
Safety is not well established. Main concerns include injection risks, product-quality problems, unknown long-term effects, interactions, sports rules, and delayed diagnosis of a real injury.
Athletes should be especially cautious. Research peptides may raise health, product-quality, and anti-doping concerns. A sports medicine clinician can help with diagnosis, rehab, and rule-compliant options.
References
- 1.Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021.
- 2.Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024.
- 3.ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair. NCT07437547. 2026.
- 4.ClinicalTrials.gov. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. NCT07803250. 2026.
- 5.Choudry FA, Yeo C, Mozid A, et al. Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement. Regenerative Medicine. 2015.
- 6.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019.
- 7.Sikiric P, Gojkovic S, Knezevic M, et al. Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways. Current Medicinal Chemistry. 2023.
- 8.ClinicalTrials.gov. A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. NCT07752381. 2026.
- 9.ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial. NCT02637284. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
